8-K Announcements
6Material company update
May 21, 2026·SEC
Material company update
May 12, 2026·SEC
Material company update
Mar 30, 2026·SEC
PepGen Inc.(PEPG)Earnings, Financials & Key Ratios
PEPG•NASDAQ
$2.05
Price updated Jul 7, 2026
AboutPepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$0
- EBITDA-$92M+4.2%
- Net Income-$90M+0.4%
- EPS (Diluted)-2.12+25.6%
- ROE-67.39%+15.0%
PEPG Price & Volume
PepGen Inc. (PEPG) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Challenges Capital Runway Sustainability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical binary funding risk
Key Thesis Takeaways
- PepGen remains in a high-risk, pre-revenue clinical development phase, with its valuation heavily dependent on the success of its EDO platform.
- The company faces significant capital intensity, as evidenced by quarterly R&D expenditures that reached $25.4 million in 2025Q1, necessitating careful monitoring of its eroding cash reserves.
- Investors should remain cautious regarding potential dilutive financing requirements, given that the current cash balance of $42.1 million is rapidly depleting against ongoing operational losses.
Verdict Logic
the company's cash and equivalents have declined significantly to $42.1 million as of 2026Q1, suggesting a high probability of near-term dilutive financing to sustain its $12.7 million quarterly R&D burn rate.
PEPG Growth Metrics
PepGen Inc. (PEPG) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM24.42%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM32.91%
Return on Capital
10 Years-47.49%
5 Years-54%
3 Years-63.65%
Last Year-63.37%
PEPG Recent Earnings
PepGen Inc. (PEPG) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.26+16.1%
$0.31
Rev
—
—
Q2 2026
Mar 4, 2026Metric
Actual
Est
EPS
$0.27+32.5%
$0.40
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.52+17.5%
$0.63
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.70+17.6%
$0.85
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.26vs $0.31+16.1% | — |
| Q2 2026 | Mar 4, 2026 | $0.27vs $0.40+32.5% | — |
| Q4 2025 | Nov 12, 2025 | $0.52vs $0.63+17.5% | — |
| Q3 2025 | Aug 7, 2025 | $0.70vs $0.85+17.6% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for PepGen Inc. (PEPG)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.05 | $141.8M | -0.97 | — | — | -67.39% | — | |
| $19.79 | $2.09B | -2.78 | 15.58% | 2.98% | 4.89% | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $35.87 | $3.53B | -6.15 | 20.13% | -91.03% | — | — | |
| $60.77 | $5.86B | -9.39 | -89.97% | -13856.54% | -30.88% | — | |
| $3.75 | $367.15M | -2.08 | 25.39% | -281.59% | -677.39% | — |
Compare PEPG vs Peers
PepGen Inc. (PEPG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PEPG SEC Filings & Documents
PepGen Inc. (PEPG) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when PEPG posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PEPG Frequently Asked Questions
PepGen Inc. (PEPG) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is PEPG profitable?
PepGen Inc. (PEPG) reported a net loss of $77.2M for fiscal year 2025.
Dividend & Returns
What is PEPG's return on equity?
PepGen Inc. (PEPG) has a return on equity (ROE) of -67.4%. Negative ROE indicates the company is unprofitable.
What is PepGen Inc.'s free cash flow?
PepGen Inc. (PEPG) had negative free cash flow of $77.3M in fiscal year 2025, likely due to heavy capital investments.